| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702664 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
The question of how best to not treat prostate cancer is often more complex than policies of universal treatment, yet is integral to minimize morbidity of over-treatment in patients with low-risk tumors. An array of refined risk stratification instruments, biomarkers, and genomic assays seek to improve the confidence both prior to, and following diagnosis.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michael S. M.D., Peter R. M.D., M.P.H.,